We have not explained this story yet. The original headline, summary and link are below.

Charles River Laboratories (CRL) stock is trading near its 52-week high despite a reported decline in Q2 revenue and a GAAP net loss. Several analysts, including Mizuho, JPMorgan, TD Cowen, and Robert W. Baird, have raised their price targets for CRL, indicating confidence in its long-term prospects. The company has also reaffirmed its 2026 organic revenue growth guidance and increased its non-GAAP EPS outlook, while projecting significant savings and growth for 2027-2030.